stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) EBITDA
Haemonetics Corporation's EBITDA for fiscal 2026 was $274.3M, down 22.2% from $352.4M in fiscal 2025. Over the twelve months to 30 June 2026 it was $273.8M. Over the past ten years it has ranged from $46.0M (fiscal 2016) to $352.4M (fiscal 2025); the current reading is higher than 92% of that period. Haemonetics Corporation ranks 19th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $274.3M | (22.16%) |
| FY2025 | $352.4M | 32.74% |
| FY2024 | $265.4M | 6.46% |
| FY2023 | $249.3M | 37.07% |
| FY2022 | $181.9M | 4.18% |
| FY2021 | $174.6M | (18.50%) |
| FY2020 | $214.2M | 11.02% |
| FY2019 | $193.0M | 32.71% |
| FY2018 | $145.4M | 106.68% |
| FY2017 | $70.4M | 53.04% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $84.6M | 1,869.47% |
| Mar 2026 | $4.3M | (95.53%) |
| Dec 2025 | $96.1M | 8.22% |
| Sep 2025 | $88.8M | 4.39% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ITGR Integer Holdings Corporation compare | $296.5M |
| HAE Haemonetics Corporation | $273.8M |
| LIVN LivaNova PLC compare | $272.6M |
| BRKR Bruker Corporation compare | $158.7M |
| IRTC iRhythm Holdings, Inc. compare | $1.5M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| TXG 10x Genomics compare | −$40.4M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on HAE
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement